Ladasten: pharmaceutical composition — RU2376986C2
Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Борис Михайлович Пятин (RU), Борис Михайлович Пятин, Нина Ивановна Авдюнина (RU), Нина Ивановна Авдюнина, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевская (RU), Любовь Николаевна Грушевская, Александр Сергеевич Сульдин (RU), Александр Сергеевич Сульдин · 2009 · RU2376986C2 · patent family 41643188
Published 2009-12-27.
Reported patent results
Reported findings
The disclosure reports acceptable tablet disintegration and mechanical properties.
Ladasten tablet manufacturing examples and physical-quality testing.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Example tablet disintegration | 6–7 minutes | A reported manufacturing-example result, not onset of clinical action |
| Direct-compression tablet properties | Compressive strength 47.81 ± 1.5 N; abrasion resistance 99.7 ± 0.6% | Physical formulation measurements; table also specifies disintegration ≤15 minutes |
Tablet properties do not establish bioequivalence, clinical anxiolytic benefit or faster symptom relief. Acceptance limits and measured example values are distinct.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The claims concern a formulated Ladasten preparation, including the active ingredient and excipients.
A formulation claim is narrower than ownership of every use of bromantane and does not establish comparative clinical benefit.
- Publication
- RU2376986C2 ↗ · 2009-12-27
- Earliest priority / filing
- 2006-11-30 / 2006-11-30
- Original applicant / assignee
- Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41643188 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition based on ladasten
Inventors: Сергей Борисович Середенин (RU); Сергей Борисович Середенин; Борис Михайлович Пятин (RU); Борис Михайлович Пятин; Нина Ивановна Авдюнина (RU); Нина Ивановна Авдюнина; Константин Викторович Алексеев (RU); Константин Викторович Алексеев; Любовь Николаевна Грушевская (RU); Любовь Николаевна Грушевская; Александр Сергеевич Сульдин (RU); Александр Сергеевич Сульдин.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A formulation claim is narrower than ownership of every use of bromantane and does not establish comparative clinical benefit.
- Tablet properties do not establish bioequivalence, clinical anxiolytic benefit or faster symptom relief. Acceptance limits and measured example values are distinct.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-41643188. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Борис Михайлович Пятин (RU), Борис Михайлович Пятин, Нина Ивановна Авдюнина (RU), Нина Ивановна Авдюнина, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевская (RU), Любовь Николаевна Грушевская, Александр Сергеевич Сульдин (RU), Александр Сергеевич Сульдин. Ladasten: pharmaceutical composition — RU2376986C2 RU2376986C2 · patent family 41643188 2009.
Molekul research summary: https://molekul.io/research/patent-ru2376986c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry